{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:47:39Z","timestamp":1793170059342,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024YFFK0150"],"award-info":[{"award-number":["2024YFFK0150"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01882-x","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:56:47Z","timestamp":1761893807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multidimensional analysis reveals the potential of ACSL3 as a cancer biomarker: from pan-cancer exploration to functional validation in hepatocellular carcinoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Qun","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiJian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"1882_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"1882_CR2","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, Al Bakir M, Hamilton EG, et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell. 2024;187:1617\u201335.","journal-title":"Cell"},{"key":"1882_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299\u2013309.","journal-title":"Nature"},{"key":"1882_CR4","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429260902230925044009","volume":"17","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Gu J, Yu H, et al. Screening and identification of ESR1 as a target of Icaritin in hepatocellular carcinoma: evidence from bibliometrics and bioinformatic analysis. Curr Mol Pharmacol. 2024;17:e18761429260902.","journal-title":"Curr Mol Pharmacol"},{"key":"1882_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41598-024-83714-8","volume":"15","author":"J Pang","year":"2025","unstructured":"Pang J, Huang X, Gao Y, et al. Multiomics analysis reveals the involvement of NET1 in tumour immune regulation and malignant progression. Sci Rep. 2025;15:56.","journal-title":"Sci Rep"},{"key":"1882_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2174\/0109298665330781240830042601","volume":"31","author":"W Ye","year":"2024","unstructured":"Ye W, Wang J, Zheng J, Jiang M, Zhou Y, Wu Z. Association between higher expression of Vav1 in hepatocellular carcinoma and unfavourable clinicopathological features and prognosis. Protein Pept Lett. 2024;31:706\u201313.","journal-title":"Protein Pept Lett"},{"key":"1882_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27\u201347.","journal-title":"Cell Metab"},{"key":"1882_CR8","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2174\/0115665232308821240826075513","volume":"25","author":"L Qi","year":"2025","unstructured":"Qi L, Tan Y, Zhou Y, et al. Proteogenomic identification and analysis of KIF5B as a prognostic signature for hepatocellular carcinoma. Curr Gene Ther. 2025;25:532\u201345.","journal-title":"Curr Gene Ther"},{"key":"1882_CR9","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.devcel.2021.04.013","volume":"56","author":"LA Broadfield","year":"2021","unstructured":"Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell. 2021;56:1363\u201393.","journal-title":"Dev Cell"},{"key":"1882_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/0113892029273682240111052317","volume":"25","author":"R Mu","year":"2024","unstructured":"Mu R, Chang M, Feng C, et al. Analysis of the expression of PRDX6 in patients with hepatocellular carcinoma and its effect on the phenotype of hepatocellular carcinoma cells. Curr Genomics. 2024;25:2\u201311.","journal-title":"Curr Genomics"},{"key":"1882_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-nutr-071813-105541","volume":"34","author":"TJ Grevengoed","year":"2014","unstructured":"Grevengoed TJ, Klett EL, Coleman RA. Acyl-CoA metabolism and partitioning. Annu Rev Nutr. 2014;34:1\u201330.","journal-title":"Annu Rev Nutr"},{"key":"1882_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plipres.2015.04.001","volume":"59","author":"D Neess","year":"2015","unstructured":"Neess D, Bek S, Engelsby H, Gallego SF, F\u00e6rgeman NJ. Long-chain acyl-CoA esters in metabolism and signaling: role of acyl-CoA binding proteins. Prog Lipid Res. 2015;59:1\u201325.","journal-title":"Prog Lipid Res"},{"key":"1882_CR13","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1083\/jcb.201305142","volume":"203","author":"A Kassan","year":"2013","unstructured":"Kassan A, Herms A, Fern\u00e1ndez-Vidal A, et al. Acyl-CoA synthetase 3 promotes lipid droplet biogenesis in ER microdomains. J Cell Biol. 2013;203:985\u20131001.","journal-title":"J Cell Biol"},{"key":"1882_CR14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1194\/jlr.M081679","volume":"59","author":"H Kimura","year":"2018","unstructured":"Kimura H, Arasaki K, Ohsaki Y, et al. Syntaxin 17 promotes lipid droplet formation by regulating the distribution of acyl-CoA synthetase 3. J Lipid Res. 2018;59:805\u201319.","journal-title":"J Lipid Res"},{"key":"1882_CR15","first-page":"606","volume":"21","author":"S Tan","year":"2024","unstructured":"Tan S, Sun X, Dong H, et al. ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1\/YAP axis. Cancer Biol Med. 2024;21:606\u201335.","journal-title":"Cancer Biol Med"},{"key":"1882_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-022-01297-1","volume":"15","author":"Y Xie","year":"2022","unstructured":"Xie Y, Wang B, Zhao Y, et al. Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis. J Hematol Oncol. 2022;15:72.","journal-title":"J Hematol Oncol"},{"key":"1882_CR17","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1111\/cas.13339","volume":"108","author":"T Migita","year":"2017","unstructured":"Migita T, Takayama KI, Urano T, et al. Acsl3 promotes intratumoral steroidogenesis in prostate cancer cells. Cancer Sci. 2017;108:2011\u201321.","journal-title":"Cancer Sci"},{"key":"1882_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40170-022-00290-z","volume":"10","author":"TD Klasson","year":"2022","unstructured":"Klasson TD, LaGory EL, Zhao H, et al. ACSL3 regulates lipid droplet biogenesis and ferroptosis sensitivity in clear cell renal cell carcinoma. Cancer Metab. 2022;10:14.","journal-title":"Cancer Metab"},{"key":"1882_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166492","volume":"1868","author":"Q Niu","year":"2022","unstructured":"Niu Q, Hou W, Yan Y, et al. Antileukemic effects of topoisomerase I inhibitors mediated by de-SUMOylase SENP1. Biochimica et Biophysica Acta (BBA). 2022;1868:166492.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"1882_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-021-00781-x","volume":"19","author":"H Prendeville","year":"2022","unstructured":"Prendeville H, Lynch L. Diet, lipids, and antitumor immunity. Cell Mol Immunol. 2022;19:432\u201344.","journal-title":"Cell Mol Immunol"},{"key":"1882_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41568-022-00543-5","volume":"23","author":"DA Guertin","year":"2023","unstructured":"Guertin DA, Wellen KE. Acetyl-CoA metabolism in cancer. Nat Rev Cancer. 2023;23:156\u201372.","journal-title":"Nat Rev Cancer"},{"key":"1882_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41392-020-00216-5","volume":"5","author":"D Li","year":"2020","unstructured":"Li D, Li Y. The interaction between ferroptosis and lipid metabolism in cancer. Signal Transduct Target Ther. 2020;5:108.","journal-title":"Signal Transduct Target Ther"},{"key":"1882_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41419-025-07516-0","volume":"16","author":"Y Cao","year":"2025","unstructured":"Cao Y, Li J, Chen Y, et al. Monounsaturated fatty acids promote cancer radioresistance by inhibiting ferroptosis through ACSL3. Cell Death Dis. 2025;16:184.","journal-title":"Cell Death Dis"},{"issue":"6","key":"1882_CR24","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.celrep.2016.07.009","volume":"16","author":"MS Padanad","year":"2016","unstructured":"Padanad MS, Konstantinidou G, Venkateswaran N, et al. Fatty acid oxidation mediated by Acyl-CoA synthetase long chain 3 is required for mutant KRAS lung tumorigenesis. Cell Rep. 2016;16(6):1614\u201328.","journal-title":"Cell Rep"},{"key":"1882_CR25","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1128\/MCB.05704-11","volume":"31","author":"D Wang","year":"2011","unstructured":"Wang D, Zavadil J, Martin L, et al. Inhibition of nonsense-mediated RNA decay by the tumor microenvironment promotes tumorigenesis. Mol Cell Biol. 2011;31:3670\u201380.","journal-title":"Mol Cell Biol"},{"key":"1882_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"key":"1882_CR27","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/0008-5472.CAN-19-2994","volume":"80","author":"P Su","year":"2020","unstructured":"Su P, Wang Q, Bi E, et al. Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Cancer Res. 2020;80:1438\u201350.","journal-title":"Cancer Res"},{"key":"1882_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36\u201350.","journal-title":"Cell Metab"},{"key":"1882_CR29","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761\u201374.","journal-title":"Nat Rev Cancer"},{"key":"1882_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12863","volume":"91","author":"P Vidal","year":"2020","unstructured":"Vidal P. Interferon \u03b1 in cancer immunoediting: from elimination to escape. Scand J Immunol. 2020;91:e12863.","journal-title":"Scand J Immunol"},{"key":"1882_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s12967-025-06473-8","volume":"23","author":"HX Li","year":"2025","unstructured":"Li HX, He YM, Fei J, et al. The G-quadruplex ligand CX-5461: an innovative candidate for disease treatment. J Transl Med. 2025;23:457.","journal-title":"J Transl Med"},{"key":"1882_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrc3483","volume":"13","author":"A Carracedo","year":"2013","unstructured":"Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer. 2013;13:227\u201332.","journal-title":"Nat Rev Cancer"},{"key":"1882_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","volume":"122","author":"N Koundouros","year":"2020","unstructured":"Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4\u201322.","journal-title":"Br J Cancer"},{"key":"1882_CR34","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1038\/s41388-021-01880-9","volume":"40","author":"X Liu","year":"2021","unstructured":"Liu X, Li L, Si F, et al. NK and NKT cells have distinct properties and functions in cancer. Oncogene. 2021;40:4521\u201337.","journal-title":"Oncogene"},{"key":"1882_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/JLB.MR0318-097R","volume":"105","author":"D Chraa","year":"2019","unstructured":"Chraa D, Naim A, Olive D, Badou A. T lymphocyte subsets in cancer immunity: friends or foes. J Leukoc Biol. 2019;105:243\u201355.","journal-title":"J Leukoc Biol"},{"key":"1882_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217347","volume":"608","author":"HT Lind","year":"2025","unstructured":"Lind HT, Hall SC, Strait AA, et al. MHC class I upregulation contributes to the therapeutic response to radiotherapy in combination with anti-PD-L1\/anti-TGF-\u03b2 in squamous cell carcinomas with enhanced CD8 T cell memory-driven response. Cancer Lett. 2025;608:217347.","journal-title":"Cancer Lett"},{"key":"1882_CR37","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450\u201361.","journal-title":"Cancer Cell"},{"key":"1882_CR38","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3390\/ijms22041726","volume":"22","author":"C Romei","year":"2021","unstructured":"Romei C, Elisei R. A narrative review of genetic alterations in primary thyroid epithelial cancer. Int J Mol Sci. 2021;22:1726.","journal-title":"Int J Mol Sci"},{"key":"1882_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.molonc.2007.01.004","volume":"1","author":"Z Herceg","year":"2007","unstructured":"Herceg Z, Hainaut P. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. Mol Oncol. 2007;1:26\u201341.","journal-title":"Mol Oncol"},{"key":"1882_CR40","doi-asserted-by":"publisher","first-page":"1483454","DOI":"10.3389\/fonc.2024.1483454","volume":"14","author":"X Yin","year":"2024","unstructured":"Yin X, Song Y, Deng W, Blake N, Luo X, Meng J. Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy. Front Oncol. 2024;14:1483454.","journal-title":"Front Oncol"},{"key":"1882_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s13258-024-01601-y","author":"HS Kim","year":"2024","unstructured":"Kim HS, Eun JW, Jang SH, Kim JY, Jeong JY. The diverse landscape of RNA modifications in cancer development and progression. Genes Genomics. 2024. https:\/\/doi.org\/10.1007\/s13258-024-01601-y.","journal-title":"Genes Genomics"},{"key":"1882_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/cancers13030545","volume":"13","author":"A Mehdi","year":"2021","unstructured":"Mehdi A, Rabbani SA. Role of methylation in pro- and anti-cancer immunity. Cancers (Basel). 2021;13:545.","journal-title":"Cancers (Basel)"}],"updated-by":[{"DOI":"10.1007\/s10238-025-01981-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000}}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01882-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01882-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01882-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:51:20Z","timestamp":1764917480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01882-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1882"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01882-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10238-025-01981-9","URL":"https:\/\/doi.org\/10.1007\/s10238-025-01981-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research was conducted in accordance with the guidelines outlined in the Declaration of Basel (\n                      \n                      ). All experimental protocols involving animals received approval from the Ethics Committee of Chengdu University of Traditional Chinese Medicine (approval number: 2025069).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study does not present details, images, or videos that can identify an individual; as such, the informed consent already obtained from all participants, as previously detailed, is considered sufficient without requiring additional publication consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"351"}}